← Back to Clinical Trials
Recruiting NCT04736381

NCT04736381 Impact of the Microbiota on the Likelihood of Renal Graft Rejection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04736381
Status Recruiting
Phase
Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Condition Kidney Transplant Rejection
Study Type OBSERVATIONAL
Enrollment 70 participants
Start Date 2021-10-07
Primary Completion 2027-01-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type OBSERVATIONAL
Interventions
Belatacept Injection [Nulojix]

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 70 participants in total. It began in 2021-10-07 with a primary completion date of 2027-01-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.

Eligibility Criteria

Inclusion Criteria: * Patients called for a kidney transplant * Induction therapy with Simulect, maintenance therapy with Nulojix, mycophenolate acid and steroids * Patient having signed the informed consent Exclusion Criteria: * Multiple grafts combined or sequential * Induction therapy with polyclonal antibodies * HIV or active viral infection such as hepatitis B or C * Active bacterial infection * Pregnancy or breastfeeding at time of inclusion * Patient unable to express their consent

Contact & Investigator

Central Contact

Antoine Durrbach, MD-PhD

✉ antoine.durrbach@inserm.fr

📞 +33614112981

Principal Investigator

Antoine Durrbach, MD-PhD

PRINCIPAL INVESTIGATOR

Institut National de la Santé Et de la Recherche Médicale, France

Frequently Asked Questions

Who can join the NCT04736381 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Kidney Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04736381 currently recruiting?

Yes, NCT04736381 is actively recruiting participants. Contact the research team at antoine.durrbach@inserm.fr for enrollment information.

Where is the NCT04736381 trial being conducted?

This trial is being conducted at Besançon, France, La Tronche, France, Nantes, France, Paris, France and 5 additional locations.

Who is sponsoring the NCT04736381 clinical trial?

NCT04736381 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The principal investigator is Antoine Durrbach, MD-PhD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology